Daily GLP-1 pill effective for diabetes and obesity, Eli Lilly says

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and Ozempic, the company announced Thursday. The once-daily pill, called orforglipron, helped patients with Type 2 diabetes lower their drug sugar levels and lose weight during late-stage trials, the drugmaker said. The trial results are being...